fda pulls tirzepatide 🚨 Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like semaglutide and tirzepatide, signaling a major shift in how these Tirzepatide is NO longer in

Read article GLP-1 and Muscle Loss: The 2026 Evidence GLP-1 muscle loss in 2026: see what the STEP and SURMOUNT trials show about lean mass and the two protective strategies that help

Flexible Payment Options Choose from secure payment options including SINPE Mvil, Zelle, PayPal, or cash for smooth and convenient transactions.Transparency & Documentatio Transparency & Documentation We provide Certificates of Analysis along with clear communication, verified stock, and straightforward pricing for complete trust

Isolated diastolic hypertension and risk of cardiovascular events: a systematic review and meta-analysis of cohort studies with 489,814 participants

There are currently no FDA-approved drug therapies for MASH, and the disease is characterized by excess fat accumulation and inflammation in the liver, which leads to liver scarring or fibrosis

Obesity, Chronic Kidney Disease, and Cardiovascular Diseases Obesity has an increasing prevalence, estimated to be 42% in the United States in 20172018 (106)